Latest Breaking News On - Janine bogris - Page 1 : comparemela.com

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Lexeo Therapeutics to Participate in Upcoming Investor Conferences
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkStephen jasperJanine bogrisLife sciences conference onHealth care conference onLexeo therapeutics incUpcoming investorSciences conferenceHealthcare conferenceAmerica securitiesCare conferenceNew york city based

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer s Disease -April 11, 2024 at 07:02 am EDT

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer s Disease -April 11, 2024 at 07:02 am EDT
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesJanine bogrisMark littonSecurities exchangeAthira pharma incExchange commissionKevin churchAttenuates amyloid beta toxicityPreclinical modelsChief scientific officerChief executive officerScientific publicationsAthira pharmaSecurities actSecurities exchange actPrivate securities litigation reform act

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Presentation to highlight therapeutic potential of Athira’s small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s.

United statesAthira pharmaJanine bogrisKevin churchSecurities exchangeAmerican academy of neurologyAthira pharma incExchange commissionAmerican academyTargeting neurotrophicPoster sessionGeneral neurologyChief scientific officerScientific publicationsSecurities actSecurities exchange act

Lexeo Therapeutics Announces Closing of Oversubscribed

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing .

United statesNew yorkJanine bogrisLaurence wattsLexeo therapeutics incNovo holdingsCompany common stockExchange commissionAdage capital partnersSurveyor capitalEventide asset managementLaurion capital managementLongitude capitalOmega fundsWoodline partnersSecurities act

Lexeo Therapeutics to Present at the 42nd Annual J P Morgan Healthcare Conference

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 8:15 AM PT in San Francisco, California. The event will be we

United statesNew yorkSan franciscoJanine bogrisR nolan townsendLaurence wattsLexeo therapeutics incChief executive officerLexeo therapeuticsHealthcare conferenceNew york city basedAlzheimer 39s diseaseGenetic medicineCardiovascular diseases